Compare Fulford India with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs SHASUN PHARMA - Comparison Results

FULFORD INDIA     Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA SHASUN PHARMA FULFORD INDIA/
SHASUN PHARMA
 
P/E (TTM) x 398.8 123.9 321.8% View Chart
P/BV x 6.2 8.5 72.8% View Chart
Dividend Yield % 0.1 0.2 36.3%  

Financials

 FULFORD INDIA   SHASUN PHARMA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
SHASUN PHARMA
Mar-14
FULFORD INDIA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs94294 1,000.0%   
Low Rs45046 986.8%   
Sales per share (Unadj.) Rs691.4214.2 322.8%  
Earnings per share (Unadj.) Rs11.55.3 214.8%  
Cash flow per share (Unadj.) Rs15.415.8 97.1%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.31.4 20.1%  
Book value per share (Unadj.) Rs380.053.3 712.4%  
Shares outstanding (eoy) m3.9056.62 6.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.00.3 308.5%   
Avg P/E ratio x60.713.1 463.6%  
P/CF ratio (eoy) x45.34.4 1,025.6%  
Price / Book Value ratio x1.81.3 139.8%  
Dividend payout %17.418.7 93.1%   
Avg Mkt Cap Rs m2,7143,958 68.6%   
No. of employees `0000.4NA-   
Total wages/salary Rs m5052,164 23.3%   
Avg. sales/employee Rs Th6,073.0NM-  
Avg. wages/employee Rs Th1,137.4NM-  
Avg. net profit/employee Rs Th100.7NM-  
INCOME DATA
Net Sales Rs m2,69612,127 22.2%  
Other income Rs m125229 54.7%   
Total revenues Rs m2,82212,356 22.8%   
Gross profit Rs m-461,009 -4.6%  
Depreciation Rs m15594 2.6%   
Interest Rs m10415 2.3%   
Profit before tax Rs m54230 23.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m10-73 -13.2%   
Profit after tax Rs m45302 14.8%  
Gross profit margin %-1.78.3 -20.7%  
Effective tax rate %17.7-31.7 -55.8%   
Net profit margin %1.72.5 66.5%  
BALANCE SHEET DATA
Current assets Rs m1,7386,884 25.2%   
Current liabilities Rs m5458,456 6.4%   
Net working cap to sales %44.3-13.0 -341.6%  
Current ratio x3.20.8 392.0%  
Inventory Days Days4862 78.6%  
Debtors Days Days4108 4.0%  
Net fixed assets Rs m124,970 0.2%   
Share capital Rs m39113 34.4%   
"Free" reserves Rs m1,4432,875 50.2%   
Net worth Rs m1,4823,020 49.1%   
Long term debt Rs m01,817 0.0%   
Total assets Rs m2,07713,347 15.6%  
Interest coverage x6.71.6 432.3%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.30.9 142.9%   
Return on assets %2.65.4 48.6%  
Return on equity %3.010.0 30.2%  
Return on capital %4.313.3 32.3%  
Exports to sales %046.4 0.0%   
Imports to sales %24.514.2 171.6%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs m6591,728 38.2%   
Fx inflow Rs m175,843 0.3%   
Fx outflow Rs m6732,173 31.0%   
Net fx Rs m-6563,669 -17.9%   
CASH FLOW
From Operations Rs m90398 22.6%  
From Investments Rs m105-1,635 -6.4%  
From Financial Activity Rs m-141,309 -1.1%  
Net Cashflow Rs m18171 253.5%  

Share Holding

Indian Promoters % 0.0 39.2 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 3.6 105.6%  
FIIs % 0.1 17.6 0.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 39.6 53.5%  
Shareholders   4,783 20,750 23.1%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare FULFORD INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA - STRIDES PHARMA SCIENCE COMPARISON

COMPARE FULFORD INDIA WITH

MARKET STATS